Aurora Cannabis Framtida tillväxt
Future kriterier kontrolleras 4/6
Aurora Cannabis förväntas öka vinsten och intäkterna med 101.8% och 8% per år respektive medan EPS förväntas växa med 80.5% per år.
Viktig information
101.8%
Tillväxttakt i vinsten
80.46%
Tillväxttakt för EPS
| Pharmaceuticals vinsttillväxt | 12.6% |
| Intäkternas tillväxttakt | 8.0% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 06 Aug 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Jul 27
ACB: Medical Refocus And Impairment Charges Will Shape Balanced Outlook
Analysts have revised their fair value estimate for Aurora Cannabis, reducing it from CA$5.00 to CA$4.00. They cite updated assumptions regarding revenue growth, profit margins, and a slightly lower future P/E multiple.
Uppdatering av berättelse • Jul 07
ACB: Medical Focus And Rescheduling Tailwinds Will Drive Future Upside Potential
Aurora Cannabis’ updated analyst price target has moved from CA$10.00 to CA$8.00 as analysts factor in lower modeled profit margins, a higher discount rate, and more conservative revenue growth assumptions, despite viewing recent partial cannabis rescheduling efforts as extremely favorable for the sector. What is in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining a plan to exit lower margin Canadian consumer and plant propagation businesses and concentrate resources on global medical cannabis, with a focus on markets such as Germany and Poland.
Uppdatering av berättelse • Jun 23
ACB: Favorable Rescheduling Outlook Will Support Shift To Global Medical Focus
Analysts have revised their fair value estimate for Aurora Cannabis from CA$7.93 to CA$6.14, citing updated expectations for revenue growth, profit margins, and a higher future P/E multiple following recent research that views partial cannabis rescheduling as extremely favorable for the sector. What’s in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining plans to exit lower margin Canadian consumer and plant propagation businesses and to concentrate resources on global medical cannabis, with a focus on what the company views as higher return opportunities.Uppdatering av berättelse • Jun 05
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.Uppdatering av berättelse • May 09
ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.Uppdatering av berättelse • Apr 20
ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.Uppdatering av berättelse • Apr 05
ACB: Revised P E Assumptions And Policy Signals Will Guide Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1 as analysts factor in updated views on revenue trends, margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent research updates point to a more cautious tone around Aurora Cannabis, as analysts reassess what they are willing to pay for the stock in light of current revenue and margin expectations.Uppdatering av berättelse • Mar 22
ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.Uppdatering av berättelse • Mar 07
ACB: Policy Shifts And Margin Execution Will Shape Fairly Balanced Outlook
Narrative update overview The latest analyst update trims the Aurora Cannabis price target by CA$1. This reflects a shift to lower expected profit margins and a higher assumed future P/E multiple, while still leaning on prior bullish initiation as support for the longer-term story.Uppdatering av berättelse • Feb 21
ACB: Policy Shift And Execution Uncertainty Will Shape Balanced Risk Profile
Aurora Cannabis: Narrative Update Analysts reduced their 12-month price target for Aurora Cannabis by CA$1. This reflects updated expectations that now assume slightly softer revenue growth, somewhat higher profit margins, and a lower future P/E multiple.Uppdatering av berättelse • Feb 06
ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead
Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.Analysartikel • Nov 07
Aurora Cannabis Inc. (TSE:ACB) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...Analysartikel • Oct 03
Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Aug 29
Aurora Cannabis Inc. (TSE:ACB) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Aurora Cannabis Inc. ( TSE:ACB ) shares have had a really impressive month, gaining 27% after a shaky period...Uppdatering av berättelse • Aug 07
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92. What's in the News Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).Analysartikel • Jul 12
Aurora Cannabis Inc. (TSE:ACB) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...Analysartikel • Jun 26
Aurora Cannabis' (TSE:ACB) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Aurora Cannabis Inc. ( TSE:ACB ) recently. We did some...Analysartikel • May 23
After Leaping 29% Aurora Cannabis Inc. (TSE:ACB) Shares Are Not Flying Under The Radar
Those holding Aurora Cannabis Inc. ( TSE:ACB ) shares would be relieved that the share price has rebounded 29% in the...
Ny berättelse • Apr 26
EU GMP And TGA Expertise Will Expand Global Cannabis Reach
Strategic international expansion and regulatory changes in key markets could significantly boost future revenues and medical cannabis margins.Analysartikel • Feb 04
Investors Give Aurora Cannabis Inc. (TSE:ACB) Shares A 26% Hiding
Unfortunately for some shareholders, the Aurora Cannabis Inc. ( TSE:ACB ) share price has dived 26% in the last thirty...Analysartikel • Nov 22
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shareholders that were waiting for something to happen have been dealt a blow with a...Analysartikel • Aug 02
It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Key Insights Aurora Cannabis to hold its Annual General Meeting on 9th of August Salary of CA$773.6k is part of CEO...Analysartikel • Jun 27
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 3/31/2029 | 354 | 24 | 23 | 43 | 3 |
| 3/31/2028 | 321 | -6 | 12 | 29 | 5 |
| 3/31/2027 | 299 | -22 | -16 | 0 | 6 |
| 6/30/2026 | 314 | -52 | -51 | -28 | N/A |
| 3/31/2026 | 321 | -59 | -36 | -14 | N/A |
| 12/31/2025 | 295 | -68 | -27 | -10 | N/A |
| 9/30/2025 | 289 | -42 | -14 | 2 | N/A |
| 6/30/2025 | 280 | 12 | 3 | 18 | N/A |
| 3/31/2025 | 289 | 27 | 1 | 16 | N/A |
| 12/31/2024 | 320 | 15 | -29 | -9 | N/A |
| 9/30/2024 | 296 | -29 | -61 | -43 | N/A |
| 6/30/2024 | 278 | -30 | -67 | -49 | N/A |
| 3/31/2024 | 270 | -53 | -85 | -69 | N/A |
| 12/31/2023 | 266 | -108 | -91 | -71 | N/A |
| 9/30/2023 | 262 | -153 | -145 | -127 | N/A |
| 6/30/2023 | 248 | -195 | -141 | -127 | N/A |
| 3/31/2023 | 224 | -793 | -163 | -142 | N/A |
| 12/31/2022 | 212 | -1,748 | -181 | -157 | N/A |
| 9/30/2022 | 210 | -1,757 | -152 | -118 | N/A |
| 6/30/2022 | 221 | -1,718 | -142 | -110 | N/A |
| 3/31/2022 | 226 | -1,233 | -98 | -64 | N/A |
| 12/31/2021 | 231 | -381 | -122 | -82 | N/A |
| 9/30/2021 | 238 | -607 | -165 | -124 | N/A |
| 6/30/2021 | 245 | -692 | -264 | -211 | N/A |
| 3/31/2021 | 257 | -2,387 | -357 | -284 | N/A |
| 12/31/2020 | 275 | -2,359 | -430 | -285 | N/A |
| 9/30/2020 | 263 | -3,342 | -614 | -357 | N/A |
| 6/30/2020 | 269 | -3,231 | -691 | -342 | N/A |
| 3/31/2020 | 299 | -1,405 | N/A | -293 | N/A |
| 12/31/2019 | 291 | -1,430 | N/A | -289 | N/A |
| 9/30/2019 | 290 | -385 | N/A | -218 | N/A |
| 6/30/2019 | 246 | -294 | N/A | -192 | N/A |
| 3/31/2019 | 168 | -211 | N/A | -233 | N/A |
| 12/31/2018 | 119 | -72 | N/A | -206 | N/A |
| 9/30/2018 | 77 | 174 | N/A | -146 | N/A |
| 6/30/2018 | 55 | 72 | N/A | -82 | N/A |
| 3/31/2018 | 42 | -13 | N/A | -35 | N/A |
| 12/31/2017 | 31 | 7 | N/A | -16 | N/A |
| 9/30/2017 | 23 | -4 | N/A | -15 | N/A |
| 6/30/2017 | 18 | -13 | N/A | -13 | N/A |
| 3/31/2017 | 13 | -16 | N/A | -17 | N/A |
| 12/31/2016 | 8 | -13 | N/A | -11 | N/A |
| 9/30/2016 | 5 | -10 | N/A | -9 | N/A |
| 6/30/2016 | 1 | -6 | N/A | -7 | N/A |
| 3/31/2016 | 0 | 0 | N/A | -5 | N/A |
| 12/31/2015 | N/A | -3 | N/A | -3 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: ACB förväntas bli lönsam under de kommande 3 åren, vilket anses vara snabbare än sparkvoten ( 3.1% ).
Resultat vs marknad: ACB förväntas bli lönsam under de kommande 3 åren, vilket anses överstiga genomsnittet på marknaden.
Höga tillväxtresultat: ACB förväntas bli lönsam under de kommande 3 åren.
Intäkt vs marknad: ACB s intäkter ( 8% per år) förväntas växa snabbare än Canadian marknaden ( 3.8% per år).
Hög tillväxtintäkter: ACB s intäkter ( 8% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om ACB s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/14 07:36 |
| Aktiekurs vid dagens slut | 2026/08/14 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Aurora Cannabis Inc. bevakas av 17 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Etienne Ricard | BMO Capital Markets Equity Research |
| Tamy Chen | BMO Capital Markets Equity Research |